Media Summary: The third of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. The second of three Q&A discussion panels for day one of the Generic Drug Forum The final Q&A discussion panel from day two of the Advancing Generic Drug Development Conference. ***No Timestamps*** ...
Agdd 2024 D1s13 Q A - Detailed Analysis & Overview
The third of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. The second of three Q&A discussion panels for day one of the Generic Drug Forum The final Q&A discussion panel from day two of the Advancing Generic Drug Development Conference. ***No Timestamps*** ... The second of three Q&A discussion panels from the FDA NIH: Regulatory Do's and Don'ts: Tips from FDA This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... The second of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference.
This presentation explained factors that could impact first-cycle bioequivalence (BE) adequacy based on observed BE ... The first of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. The second of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. This presentation identified recent product-specific guidance (PSG) documents that include detailed language regarding the use ... The first of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. FDA experts demonstrate the FDA's Generic Drug User Fee Amendments (GDUFA) Science and Research Program's ...
The final Q&A discussion panel from day one of the Advancing Generic Drug Development Conference. ***No Timestamps*** ...
